GO:0140949 histone H3K9 trimethyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140949 describes the enzymatic activity that successively adds three methyl groups to lysine 9 of histone H3, producing the repressive mark H3K9me3.
• SUV39H1 and its orthologs are the founding histone H3K9 trimethyltransferases, using S-adenosyl-L-methionine as the methyl donor [1,3].
• H3K9me3 established by this activity creates binding sites for heterochromatin proteins and is linked to transcriptional silencing [7,8].
• Dysregulated H3K9 trimethylation contributes to cancer, cardiac ischemia-reperfusion injury, diabetic retinopathy, and impaired embryonic development [2,3,4,6].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of H3K9 trimethyltransferase function [1,3].
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study GO:0140949-related genes.
Description
Histone H3 lysine 9 trimethylation (H3K9me3) is a hallmark of constitutive heterochromatin and a key epigenetic determinant of gene silencing. The enzyme activity responsible for depositing this mark is annotated as GO:0140949, histone H3K9 trimethyltransferase activity, which catalyzes the successive transfer of three methyl groups from S-adenosyl-L-methionine to lysine 9 of histone H3. This activity is essential for establishing repressive chromatin domains that regulate development, genome stability, and cell fate. Researchers study GO:0140949 to understand how epigenetic states are inherited and how their disruption contributes to disease. The founding member of this enzyme family, Su(var)3-9, was identified in Drosophila and later characterized in diverse organisms including Spodoptera frugiperda, where its H3K9 trimethyltransferase activity influences viral infection. In mammals, SUV39H1 and related SET-domain proteins mediate H3K9me3 deposition at pericentromeric heterochromatin and other loci [3,7]. Because H3K9me3 is a stable epigenetic mark, its misregulation has been implicated in cancer, cardiovascular disease, and metabolic disorders [2,3,6]. Understanding the molecular mechanism, regulation, and disease relevance of GO:0140949 is therefore a major goal in epigenetics and biomedical research.
histone H3K9 trimethyltransferase activity At A Glance
| GO ID | GO:0140949 |
|---|---|
| GO term | histone H3K9 trimethyltransferase activity |
| Ontology | molecular_function |
| Synonym | histone H3K9 mono/di/trimethylase activity; histone H3K9 trimethylase activity; histone H3-K9 trimethylation; histone H3K9 trimethylation; histone lysine N-trimethyltransferase activity (H3-K9 specific) |
| Major function | Catalyzes the successive addition of three methyl groups to lysine 9 of histone H3, producing H3K9me3 |
| Cofactor | S-adenosyl-L-methionine (SAM) as methyl donor |
| Reaction products | H3K9me3, S-adenosyl-L-homocysteine, and H+ |
| Representative enzymes | SUV39H1, SUV39H2, SETDB1, SETDB2, and orthologs such as Su(var)3-9 [1,2,3] |
What Is GO:0140949?
GO:0140949 is a molecular function term defined as the catalysis of the reaction: L-lysyl9-[histone H3] + 3 S-adenosyl-L-methionine = 3 H+ + N6,N6,N6-trimethyl-L-lysyl9-[histone H3] + 3 S-adenosyl-L-homocysteine. In simpler terms, it is the enzymatic activity that adds three methyl groups to the unmethylated lysine 9 residue of histone H3, producing histone H3K9me3. This activity is also known as histone H3K9 mono/di/trimethylase activity, histone H3K9 trimethylase activity, or histone H3-K9 trimethylation.
Why Is histone H3K9 trimethyltransferase activity Important in Cell Biology?
GO:0140949 is critical because H3K9me3 is a central epigenetic mark for heterochromatin formation, transcriptional repression, and genome stability. Dysregulation of this activity alters gene expression programs and contributes to diseases including cancer, cardiac injury, and diabetic complications [2,3,6]. Studying this activity helps researchers understand how epigenetic states are established and maintained, and provides a basis for therapeutic targeting of histone methyltransferases.
• Establishes H3K9me3, a hallmark of constitutive heterochromatin and gene silencing.
• Regulates developmental processes, including early embryonic development in pigs.
• Modulates cellular senescence through stress-induced epigenetic changes.
• Contributes to cancer immunosuppression via SETDB2-mediated splicing regulation.
• Mediates cardiac ischemia-reperfusion injury through SUV39H1-dependent SIRT1 repression.
• Influences diabetic retinopathy by regulating Rac1 transcription.
• Controls inflammatory gene expression through CIITA-mediated eNOS repression.
• Regulates adipogenesis via Suv39h1-mediated inhibition of C/EBPα.
• Serves as a target for epigenetic therapies in oncology and cardiovascular disease [2,3].
• Provides a model for studying chromatin-modifying enzyme mechanisms and inhibitor development.
Molecular Mechanism of histone H3K9 trimethyltransferase activity
Substrate recognition and binding
In simple terms: The enzyme first grabs the histone H3 protein and finds the right spot, lysine 9.
Histone H3K9 trimethyltransferases contain a conserved SET domain that recognizes the N-terminal tail of histone H3. The enzyme binds to the substrate through interactions with residues surrounding lysine 9, ensuring specificity for this position. Structural studies of Su(var)3-9 orthologs have revealed that the SET domain forms a cleft that accommodates the target lysine and positions it for methyl transfer.
Methyl group transfer from SAM
In simple terms: The enzyme uses SAM as a methyl donor to add methyl groups one by one onto lysine 9.
The catalytic mechanism involves the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the epsilon-amino group of lysine 9. This reaction proceeds through a sequential mechanism, first producing monomethylated H3K9, then dimethylated, and finally trimethylated H3K9. Each round of methylation consumes one SAM molecule and releases S-adenosyl-L-homocysteine (SAH) as a byproduct.
Processive trimethylation
In simple terms: The enzyme adds all three methyl groups in a row without letting go of the histone.
Biochemical characterization of Su(var)3-9 from Spodoptera frugiperda demonstrated that the enzyme can processively add three methyl groups to H3K9, resulting in H3K9me3. This processive activity is essential for establishing stable heterochromatin domains, as the trimethylated mark is recognized by heterochromatin protein 1 (HP1) and other readers.
Cofactor and product release
In simple terms: After adding the methyl groups, the enzyme releases the modified histone and the used-up SAM.
Following catalysis, the trimethylated H3K9 product and S-adenosyl-L-homocysteine are released from the active site. The enzyme can then bind new substrates. The reaction also produces protons (H+), as indicated in the GO definition.
Regulation by interacting proteins
In simple terms: Other proteins can turn the enzyme on or off or guide it to specific genes.
Histone H3K9 trimethyltransferase activity is regulated by interacting partners. For example, SUV39H1 is recruited to specific promoters by transcription factors such as CIITA to repress eNOS expression. Similarly, Suv39h1 mediates AP-2α-dependent inhibition of C/EBPα during adipogenesis. These interactions determine where and when H3K9me3 is deposited.
Key Genes Involved in GO:0140949 histone H3K9 trimethyltransferase activity
The following genes encode proteins with histone H3K9 trimethyltransferase activity or are directly involved in its regulation and function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SUV39H1 | Histone H3K9 trimethyltransferase; establishes heterochromatin | Cardiac ischemia-reperfusion injury, adipogenesis, eNOS repression [3,7,8] |
| SUV39H2 | Histone H3K9 trimethyltransferase; testis-specific functions | Cancer, chromatin regulation |
| SETDB1 | Histone H3K9 trimethyltransferase; involved in gene silencing | Cancer, immune regulation |
| SETDB2 | Histone H3K9 trimethyltransferase; regulates splicing and immunosuppression | Hepatocellular carcinoma |
| Su(var)3-9 | Drosophila ortholog; heterochromatin formation | Viral infection, developmental epigenetics |
| HP1 | Reader of H3K9me3; binds methylated histone | Heterochromatin assembly |
| SIRT1 | Deacetylase; repressed by SUV39H1-mediated H3K9me3 | Cardiac injury |
| CIITA | Transcription factor recruiting SUV39H1 | Inflammatory gene repression |
| AP-2α | Transcription factor cooperating with Suv39h1 | Adipogenesis |
| ATF7 | Stress-responsive transcription factor linked to H3K9me3 changes | Cellular senescence, embryonic development [4,5] |
| Rac1 | Small GTPase regulated by histone methylation | Diabetic retinopathy |
| C/EBPα | Transcription factor repressed by Suv39h1 | Adipocyte differentiation |
| eNOS | Endothelial nitric oxide synthase; repressed by H3K9me3 | Vascular inflammation |
| SHP-1 | Phosphatase regulated by SETDB2-mediated splicing | Hepatocellular carcinoma immunosuppression |
| G9a | Histone H3K9 methyltransferase (related activity) | Epigenetic silencing |
| GLP | Histone H3K9 methyltransferase (related activity) | Chromatin regulation |
How Is histone H3K9 trimethyltransferase activity Regulated?
Histone H3K9 trimethyltransferase activity is regulated at multiple levels. Transcription factors such as CIITA and AP-2α recruit SUV39H1 to specific promoters, thereby directing H3K9me3 deposition and gene repression [7,8]. Stress conditions, including high temperature and cellular senescence, can induce ATF7-dependent changes in H3K9 methylation patterns [4,5]. Additionally, the activity can be modulated by interaction with other chromatin-modifying enzymes and by the availability of the methyl donor SAM. In diabetic retinopathy, altered histone and DNA methylation regulate Rac1 transcription, implicating H3K9 trimethylation in metabolic stress responses.
histone H3K9 trimethyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SETDB2 | Hepatocellular carcinoma immunosuppression | Knockout in HCC cell lines; xenograft models |
| SUV39H1 | Cardiac ischemia-reperfusion injury | Cardiomyocyte-specific knockout mice; hypoxia-reoxygenation |
| SUV39H1 | Adipogenesis and metabolic disorders | 3T3-L1 adipocyte differentiation with Suv39h1 knockdown |
| Rac1 | Diabetic retinopathy | Retinal endothelial cells under high glucose; KO models |
| ATF7 | Embryonic development and senescence | Porcine embryos; ATF7 knockout cells [4,5] |
Cancer
Dysregulated histone H3K9 trimethyltransferase activity contributes to cancer progression. SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma, highlighting a role for H3K9me3 in tumor immune evasion. SUV39H1 and SETDB1 are frequently overexpressed in various cancers and are associated with silencing of tumor suppressor genes.
Cardiovascular disease
SUV39H1-mediated H3K9 trimethylation contributes to cardiac ischemia-reperfusion injury by repressing SIRT1, a key regulator of cellular stress responses. This epigenetic mechanism links histone methylation to myocardial damage and suggests that targeting H3K9 trimethyltransferases could be cardioprotective.
Metabolic and developmental disorders
Su(var)3-9 orthologs regulate adipogenesis through AP-2α-dependent inhibition of C/EBPα, implicating H3K9 trimethylation in metabolic disorders. In diabetic retinopathy, histone methylation regulates Rac1 transcription, contributing to retinal vascular dysfunction. Additionally, ATF7-dependent epigenetic changes during early porcine embryonic development and cellular senescence highlight roles in developmental and aging-related processes [4,5].
From histone H3K9 trimethyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SUV39H1 reduce H3K9me3 and alter gene expression? | CRISPR knockout in HEK293 or cancer cell lines |
| Does a point mutation in the SET domain abolish methyltransferase activity? | CRISPR point-mutation knock-in of catalytic residues |
| Can a tagged SUV39H1 be used to map genomic binding sites? | Knock-in of epitope-tagged SUV39H1 |
| Does overexpression of SETDB2 promote immunosuppression? | Overexpression in hepatocellular carcinoma cells |
| Does ATF7-dependent H3K9me3 change affect senescence? | ATF7 knockout or overexpression in fibroblasts |
| Does H3K9me3 regulate Rac1 transcription in diabetic retinopathy? | CRISPR knockout of SUV39H1 in retinal endothelial cells |
How to Study the histone H3K9 trimethyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide localization of H3K9me3 and enzyme binding | Mapping heterochromatin domains |
| Western blot | Global H3K9me3 levels | Validating knockout or overexpression |
| Immunofluorescence | Nuclear distribution of H3K9me3 | Visualizing heterochromatin foci |
| In vitro methyltransferase assay | Enzymatic activity and kinetics | Characterizing inhibitors |
| RNA-seq | Transcriptional changes | Identifying affected pathways |
| CRISPR screening | Functional importance of genes | Discovering modifiers of H3K9me3 |
| Proteomics | Protein interactions and modifications | Identifying enzyme complexes |
| qRT-PCR | Expression of target genes | Validating RNA-seq results |
Chromatin immunoprecipitation sequencing (ChIP-seq)
ChIP-seq using antibodies against H3K9me3 or tagged enzymes allows genome-wide mapping of histone H3K9 trimethyltransferase activity and its deposition patterns. This method is essential for identifying target loci and understanding how the enzyme is recruited to specific genes [1,7].
Western blotting and immunofluorescence
Western blotting with anti-H3K9me3 antibodies quantifies global levels of the trimethyl mark, while immunofluorescence can visualize heterochromatin foci in situ. These methods are widely used to assess changes in H3K9 trimethyltransferase activity upon genetic manipulation or drug treatment [1,3].
In vitro methyltransferase assays
Recombinant enzymes can be incubated with histone substrates and radiolabeled or fluorescent SAM to measure methyltransferase activity directly. Such assays are used to characterize enzyme kinetics, substrate specificity, and inhibitor efficacy.
RNA sequencing (RNA-seq)
RNA-seq measures changes in gene expression following knockout or overexpression of H3K9 trimethyltransferases. This approach reveals the transcriptional consequences of altered H3K9me3 and helps identify pathways affected in disease models [2,6].
How CRISPR Can Be Used to Study GO:0140949 histone H3K9 trimethyltransferase activity
Knockout
CRISPR knockout of SUV39H1, SETDB1, or SETDB2 eliminates histone H3K9 trimethyltransferase activity, leading to loss of H3K9me3 and reactivation of silenced genes. Knockout cell lines are valuable for studying the causal role of these enzymes in disease models such as cancer and cardiac injury [2,3].
Point Mutation
Introducing point mutations in the SET domain catalytic residues (e.g., replacing a key histidine or arginine) abolishes methyltransferase activity without affecting protein stability. Such point-mutation knock-in models help distinguish enzymatic activity from scaffolding functions.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into endogenous SUV39H1 or SETDB2 loci enables ChIP-seq and proteomic studies under native expression conditions. Tagged knock-in models are also useful for tracking enzyme localization and interactions.
Overexpression
Overexpression of wild-type or mutant H3K9 trimethyltransferases in cell lines can drive hypermethylation of H3K9 and alter gene expression programs. This approach is used to model diseases characterized by elevated H3K9me3, such as hepatocellular carcinoma.
How EDITGENE Supports histone H3K9 trimethyltransferase activity Research
Researchers studying histone H3K9 trimethyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes encoding H3K9 trimethyltransferases and their regulators.
Contact EDITGENE today to design your custom CRISPR model for histone H3K9 trimethyltransferase activity research.
Frequently Asked Questions About histone H3K9 trimethyltransferase activity
What is histone H3K9 trimethyltransferase activity?
It is the enzymatic activity (GO:0140949) that adds three methyl groups to lysine 9 of histone H3, producing H3K9me3, a repressive chromatin mark.
What genes are involved in histone H3K9 trimethyltransferase activity?
Key genes include SUV39H1, SUV39H2, SETDB1, SETDB2, and their orthologs such as Su(var)3-9 [1,2,3].
What is the role of H3K9me3 in gene expression?
H3K9me3 is a hallmark of heterochromatin and is associated with transcriptional silencing. It recruits reader proteins like HP1 to compact chromatin.
How is histone H3K9 trimethyltransferase activity regulated?
It is regulated by interacting transcription factors (e.g., CIITA, AP-2α), stress signals, and cofactor availability [4,5,7,8].
Which diseases are linked to H3K9 trimethyltransferase dysfunction?
Cancer, cardiac ischemia-reperfusion injury, diabetic retinopathy, and developmental disorders have been linked to altered H3K9me3 [2,3,4,6].
What methods are used to study H3K9 trimethyltransferase activity?
ChIP-seq, Western blot, in vitro methyltransferase assays, RNA-seq, and CRISPR screening are commonly used [1,2,6].
Can CRISPR knockout be used to study H3K9 trimethyltransferases?
Yes, knockout of SUV39H1 or SETDB2 eliminates H3K9me3 and reveals downstream effects on gene expression and disease phenotypes [2,3].
What is the difference between H3K9me3 and H3K9me2?
H3K9me3 is the trimethylated form associated with constitutive heterochromatin, while H3K9me2 is often found in facultative heterochromatin and euchromatic gene silencing.
How does SETDB2 contribute to cancer?
SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma.
What cell models are available for H3K9 trimethyltransferase research?
EDITGENE offers knockout, point-mutation, knock-in, and overexpression cell models for genes such as SUV39H1, SETDB1, and SETDB2.
Conclusion
GO:0140949, histone H3K9 trimethyltransferase activity, is a fundamental epigenetic activity that establishes the repressive H3K9me3 mark. Its dysregulation is implicated in cancer, cardiovascular disease, and metabolic disorders, making it a compelling target for basic and translational research. By leveraging CRISPR-based cell models and advanced screening technologies, researchers can dissect the causal roles of H3K9 trimethyltransferases and accelerate the development of epigenetic therapies.
References
- 1. Li B et al.. 2013. Identification and characterization of the Spodoptera Su(var) 3-9 histone H3K9 trimethyltransferase and its effect in AcMNPV infection.. PLoS One 8(7):e69442 PMID: 23894480
- 2. Jiao Q et al.. 2026. SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma.. Oncogene 45(19):1771-1785 PMID: 41946995
- 3. Yang G et al.. 2017. SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.. Basic Res Cardiol 112(3):22 PMID: 28271186
- 4. Sun MH et al.. 2023. ATF7-dependent epigenetic changes induced by high temperature during early porcine embryonic development.. Cell Prolif 56(2):e13352 PMID: 36254813
- 5. Maekawa T et al.. 2019. Stress-induced and ATF7-dependent epigenetic change influences cellular senescence.. Genes Cells 24(9):627-635 PMID: 31294895
- 6. Kowluru RA et al.. 2021. Regulation of Rac1 transcription by histone and DNA methylation in diabetic retinopathy.. Sci Rep 11(1):14097 PMID: 34238980
- 7. Weng X et al.. 2019. Class II transactivator (CIITA) mediates IFN-γ induced eNOS repression by enlisting SUV39H1.. Biochim Biophys Acta Gene Regul Mech 1862(2):163-172 PMID: 30716531
- 8. Zhang ZC et al.. 2014. Suv39h1 mediates AP-2α-dependent inhibition of C/EBPα expression during adipogenesis.. Mol Cell Biol 34(12):2330-8 PMID: 24732798
